A Link Between Inflammatory Mechanisms and Fibromyalgia

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2023 Mar 23

PMID 36949318

Authors

Ashika Bains

Samuel Kohrman

Diana Punko

Gregory Fricchione

Affiliations

Soon will be listed here.

Abstract

Fibromyalgia (FM) is a condition characterized by chronic widespread pain, which has traditionally been considered psychogenic in nature due to lack of known underlying organic pathophysiology. In more recent years, inflammation of the nervous system has become increasingly recognized as a sign of neuropsychiatric conditions, and this association may enhance our knowledge of conditions such as FM. Emerging evidence has suggested inflammation, particularly neuroinflammation, as a potential contributor underlying the etiology of FM. Studies have searched for linked biomarkers with mixed results, though the literature is beginning to point to increased systemic levels of pro-inflammatory cytokines such as IL-6 and IL-8 in patients with FM relative to healthy controls. A multicenter imaging study has also reported results suggestive of microglial activation related to the presence of FM. Given the consistency in neuroinflammatory effects implicated in "sickness behavior" characteristic of chronic systemic inflammatory conditions such as cancer or rheumatic diseases, therein springs the hypothesis for a connection between FM and neuroinflammation as discussed in this chapter.

Citing Articles

Fibromyalgia and Inflammation: Unrevealing the Connection.

Garcia-Dominguez M Cells. 2025; 14(4).

PMID: 39996743 PMC: 11853252. DOI: 10.3390/cells14040271.

Radio Electric Asymmetric Conveyer (REAC) Biomodulation for Chronic Pain and Functional Improvement in Rheumatoid Arthritis, Lipedema, and Fibromyalgia: A Case Study on Anti-inflammatory, Circulatory, and Metabolic Optimization.

Renck A, Fontani V, Rinaldi S Cureus. 2024; 16(11):e74311.

PMID: 39583599 PMC: 11585336. DOI: 10.7759/cureus.74311.

Heart Rate Variability Biofeedback Efficacy on Fatigue and Energy Levels in Fibromyalgia: A Secondary Analysis of RCT NCT0412183.

Carta M, Cossu G, Primavera D, Gonzalez C, Testa G, Stocchino S J Clin Med. 2024; 13(14).

PMID: 39064048 PMC: 11278324. DOI: 10.3390/jcm13144008.

Investigating the Effectiveness of a Carb-Free Oloproteic Diet in Fibromyalgia Treatment.

Castaldo G, Marino C, Atteno M, DElia M, Pagano I, Grimaldi M Nutrients. 2024; 16(11).

PMID: 38892552 PMC: 11175073. DOI: 10.3390/nu16111620.

Elevated high sensitive C-reactive protein in fibromyalgia.

Beiner E, Brenner Miguel S, Friederich H, Tesarz J Front Psychiatry. 2023; 14:1237518.

PMID: 38098640 PMC: 10720424. DOI: 10.3389/fpsyt.2023.1237518.

References

Wolfe F, Smythe H, Yunus M, Bennett R, Bombardier C, Goldenberg D . The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990; 33(2):160-72. DOI: 10.1002/art.1780330203. View

Wolfe F, Clauw D, Fitzcharles M, Goldenberg D, Hauser W, Katz R . 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016; 46(3):319-329. DOI: 10.1016/j.semarthrit.2016.08.012. View

Fillingim R, Bruehl S, Dworkin R, Dworkin S, Loeser J, Turk D . The ACTTION-American Pain Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to classifying chronic pain conditions. J Pain. 2014; 15(3):241-9. PMC: 4454364. DOI: 10.1016/j.jpain.2014.01.004. View

Arnold L, Bennett R, Crofford L, Dean L, Clauw D, Goldenberg D . AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2018; 20(6):611-628. DOI: 10.1016/j.jpain.2018.10.008. View

Jones G, Atzeni F, Beasley M, Fluss E, Sarzi-Puttini P, Macfarlane G . The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2014; 67(2):568-75. DOI: 10.1002/art.38905. View

Creed F . A review of the incidence and risk factors for fibromyalgia and chronic widespread pain in population-based studies. Pain. 2020; 161(6):1169-1176. DOI: 10.1097/j.pain.0000000000001819. View

Branco J, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M . Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2009; 39(6):448-53. DOI: 10.1016/j.semarthrit.2008.12.003. View

Wallace D, Gavin I, Karpenko O, Barkhordar F, Gillis B . Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis. Rheumatol Int. 2014; 35(6):991-6. PMC: 4435905. DOI: 10.1007/s00296-014-3172-2. View

Feng B, La J, Schwartz E, Gebhart G . Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012; 302(10):G1085-98. PMC: 3362095. DOI: 10.1152/ajpgi.00542.2011. View

10.

Hauser W, Perrot S, Sommer C, Shir Y, Fitzcharles M . Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep. 2018; 2(3):e598. PMC: 5741304. DOI: 10.1097/PR9.0000000000000598. View

11.

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397(10270):220-232. PMC: 7833295. DOI: 10.1016/S0140-6736(20)32656-8. View

12.

Nalbandian A, Sehgal K, Gupta A, Madhavan M, McGroder C, Stevens J . Post-acute COVID-19 syndrome. Nat Med. 2021; 27(4):601-615. PMC: 8893149. DOI: 10.1038/s41591-021-01283-z. View

13.

Rubin R . As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts. JAMA. 2020; 324(14):1381-1383. DOI: 10.1001/jama.2020.17709. View

14.

Franke C, Ferse C, Kreye J, Reincke S, Sanchez-Sendin E, Rocco A . High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2020; 93:415-419. PMC: 7834471. DOI: 10.1016/j.bbi.2020.12.022. View

15.

Littlejohn G, Guymer E . Neurogenic inflammation in fibromyalgia. Semin Immunopathol. 2018; 40(3):291-300. DOI: 10.1007/s00281-018-0672-2. View

16.

Miller A, Ancoli-Israel S, Bower J, Capuron L, Irwin M . Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008; 26(6):971-82. PMC: 2770012. DOI: 10.1200/JCO.2007.10.7805. View

17.

Maes M, Meltzer H, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R . Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995; 34(4):301-9. DOI: 10.1016/0165-0327(95)00028-l. View

18.

Levine J, Barak Y, Chengappa K, Rapoport A, Rebey M, Barak V . Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999; 40(4):171-6. DOI: 10.1159/000026615. View

19.

Raison C, Capuron L, Miller A . Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2005; 27(1):24-31. PMC: 3392963. DOI: 10.1016/j.it.2005.11.006. View

20.

Miller A, Raison C . The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2015; 16(1):22-34. PMC: 5542678. DOI: 10.1038/nri.2015.5. View